Minakem-flap
Minakem-flap

Find Oncology Drugs in Phase I/II Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATL001

            Therapeutic Area: Oncology Product Name: ATL001

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $175.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 30, 2021

            Details:

            Company's lead drug, ATL001, is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. it's lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EP0042

            Therapeutic Area: Oncology Product Name: EP0042

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ellipses Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2021

            Details:

            Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VAL201

            Therapeutic Area: Oncology Product Name: VAL201

            Highest Development Status: Phase I/ Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: ValiRx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 17, 2021

            Details:

            ValiRx will benefit from Physiomics' expertise in modelling the effects of prostate cancer care, as well as the latest version of its Virtual TumourTM technology, which will be used to extract useful information from the additional data provided by the VAL201 clinical trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FS118

            Therapeutic Area: Oncology Product Name: FS118

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 20, 2021

            Details:

            The EPO has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.